Abstract

Infantile hemangioma (IH), often treated with propranolol, is a benign vascular tumor that undergoes a spontaneous involution to a fibrofatty residuum. We investigated how R(+) propranolol, the non-beta blocker enantiomer of racemic propranolol, affects lipid accumulation and adipogenesis in IH. This was motivated by our previous work showing R(+) propranolol can block blood vessel formation in a pre-clinical model of IH. Our findings suggest a novel regulatory role for the R(+) propranolol in modulating lipid accumulation in HemSC. This highlights a novel role of R(+) propranolol in the involuting phase of IH and a strategy to reduce fibrofatty residua in IH.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.